AAPL344.08+0.62 (+0.18%) ▲|ABBV286.06+0.59 (+0.20%) ▲|ABT104.29-0.60 (-0.57%) ▼|ACN230.61+0.93 (+0.40%) ▲|ADBE244.41-0.79 (-0.32%) ▼|AMAT421.96+12.67 (+3.10%) ▲|AMD540.64+11.89 (+2.25%) ▲|AMGN434.25+1.76 (+0.41%) ▲|AMT183.31-1.97 (-1.06%) ▼|AMZN258.92+8.92 (+3.57%) ▲|AVGO334.25+5.50 (+1.67%) ▲|AXP312.21-1.39 (-0.44%) ▼|BA189.44-0.77 (-0.41%) ▼|BAC51.26+0.03 (+0.05%) ▲|BKNG161.16-2.29 (-1.40%) ▼|BLK1,126.78-7.61 (-0.67%) ▼|BMY59.45-0.31 (-0.51%) ▼|BNY142.95-0.35 (-0.24%) ▼|BRK-B532.17+0.15 (+0.03%) ▲|C123.90-0.36 (-0.29%) ▼|CAT722.74-8.02 (-1.10%) ▼|CL93.46-0.66 (-0.70%) ▼|CMCSA21.58-0.33 (-1.48%) ▼|COF200.20-1.54 (-0.76%) ▼|COP145.61-0.90 (-0.61%) ▼|COST989.96+0.85 (+0.09%) ▲|CRM239.21-1.49 (-0.62%) ▼|CSCO107.25-0.15 (-0.14%) ▼|CVS92.02-0.34 (-0.37%) ▼|CVX224.78-0.21 (-0.09%) ▼|DE632.60-9.26 (-1.44%) ▼|DHR227.27-1.77 (-0.77%) ▼|DIS109.58-1.01 (-0.91%) ▼|DUK120.08-1.39 (-1.14%) ▼|EMR161.30-0.17 (-0.11%) ▼|FDX293.24-0.31 (-0.11%) ▼|GD341.97-2.18 (-0.63%) ▼|GE312.56-1.27 (-0.40%) ▼|GEV921.53+0.33 (+0.04%) ▲|GILD157.11+0.92 (+0.59%) ▲|GM83.24-0.72 (-0.86%) ▼|GOOG340.45+3.54 (+1.05%) ▲|GOOGL344.08+3.49 (+1.02%) ▲|GS883.89+2.63 (+0.30%) ▲|HD307.76-1.87 (-0.60%) ▼|HON210.27-1.14 (-0.54%) ▼|IBM233.66+1.52 (+0.65%) ▲|INTC93.76+3.91 (+4.35%) ▲|INTU319.82-5.33 (-1.64%) ▼|ISRG430.82+4.12 (+0.96%) ▲|JNJ254.13-1.44 (-0.56%) ▼|JPM338.06-1.66 (-0.49%) ▼|KO93.79-0.11 (-0.12%) ▼|LIN502.01+3.58 (+0.72%) ▲|LLY1,258.36+1.33 (+0.11%) ▲|LMT545.83-6.26 (-1.13%) ▼|LOW195.77-1.61 (-0.82%) ▼|LRCX275.08+11.14 (+4.22%) ▲|MA615.91-1.51 (-0.24%) ▼|MCD241.32-1.66 (-0.68%) ▼|MDLZ63.88-0.03 (-0.05%) ▼|MDT94.07-0.68 (-0.72%) ▼|META694.58-14.75 (-2.08%) ▼|MMM162.89-1.86 (-1.13%) ▼|MO74.42-0.69 (-0.92%) ▼|MRK146.87+0.92 (+0.63%) ▲|MS180.72+0.15 (+0.08%) ▲|MSFT533.03+3.98 (+0.75%) ▲|MU908.23+29.39 (+3.34%) ▲|NEE78.59-1.21 (-1.52%) ▼|NFLX69.30-1.24 (-1.75%) ▼|NKE36.83-0.31 (-0.82%) ▼|NOW143.33+1.36 (+0.96%) ▲|NVDA215.88+1.75 (+0.82%) ▲|ORCL129.36+1.13 (+0.88%) ▲|PEP132.26+0.77 (+0.59%) ▲|PFE29.61+0.03 (+0.08%) ▲|PG158.10-1.25 (-0.78%) ▼|PLTR191.30+5.27 (+2.83%) ▲|PM202.50-2.70 (-1.32%) ▼|QCOM175.67+3.56 (+2.07%) ▲|RTX191.84-2.08 (-1.07%) ▼|SBUX97.14-0.38 (-0.39%) ▼|SCHW90.36-1.60 (-1.74%) ▼|SO89.93-1.25 (-1.37%) ▼|SPG204.06-1.38 (-0.67%) ▼|T23.27-0.18 (-0.75%) ▼|TMO688.56-1.44 (-0.21%) ▼|TMUS157.97-1.13 (-0.71%) ▼|TSLA361.84+7.12 (+2.01%) ▲|TXN276.46-0.03 (-0.01%) ▼|UBER70.27-0.09 (-0.12%) ▼|UNH404.58+3.15 (+0.78%) ▲|UNP287.20-1.84 (-0.64%) ▼|UPS97.27-0.21 (-0.22%) ▼|USB58.37-0.37 (-0.62%) ▼|V402.56-0.05 (-0.01%) ▼|VZ44.39-0.40 (-0.89%) ▼|WFC83.12-0.75 (-0.89%) ▼|WMT118.71-0.10 (-0.08%) ▼|XOM178.01-0.98 (-0.54%) ▼|AAPL344.08+0.62 (+0.18%) ▲|ABBV286.06+0.59 (+0.20%) ▲|ABT104.29-0.60 (-0.57%) ▼|ACN230.61+0.93 (+0.40%) ▲|ADBE244.41-0.79 (-0.32%) ▼|AMAT421.96+12.67 (+3.10%) ▲|AMD540.64+11.89 (+2.25%) ▲|AMGN434.25+1.76 (+0.41%) ▲|AMT183.31-1.97 (-1.06%) ▼|AMZN258.92+8.92 (+3.57%) ▲|AVGO334.25+5.50 (+1.67%) ▲|AXP312.21-1.39 (-0.44%) ▼|BA189.44-0.77 (-0.41%) ▼|BAC51.26+0.03 (+0.05%) ▲|BKNG161.16-2.29 (-1.40%) ▼|BLK1,126.78-7.61 (-0.67%) ▼|BMY59.45-0.31 (-0.51%) ▼|BNY142.95-0.35 (-0.24%) ▼|BRK-B532.17+0.15 (+0.03%) ▲|C123.90-0.36 (-0.29%) ▼|CAT722.74-8.02 (-1.10%) ▼|CL93.46-0.66 (-0.70%) ▼|CMCSA21.58-0.33 (-1.48%) ▼|COF200.20-1.54 (-0.76%) ▼|COP145.61-0.90 (-0.61%) ▼|COST989.96+0.85 (+0.09%) ▲|CRM239.21-1.49 (-0.62%) ▼|CSCO107.25-0.15 (-0.14%) ▼|CVS92.02-0.34 (-0.37%) ▼|CVX224.78-0.21 (-0.09%) ▼|DE632.60-9.26 (-1.44%) ▼|DHR227.27-1.77 (-0.77%) ▼|DIS109.58-1.01 (-0.91%) ▼|DUK120.08-1.39 (-1.14%) ▼|EMR161.30-0.17 (-0.11%) ▼|FDX293.24-0.31 (-0.11%) ▼|GD341.97-2.18 (-0.63%) ▼|GE312.56-1.27 (-0.40%) ▼|GEV921.53+0.33 (+0.04%) ▲|GILD157.11+0.92 (+0.59%) ▲|GM83.24-0.72 (-0.86%) ▼|GOOG340.45+3.54 (+1.05%) ▲|GOOGL344.08+3.49 (+1.02%) ▲|GS883.89+2.63 (+0.30%) ▲|HD307.76-1.87 (-0.60%) ▼|HON210.27-1.14 (-0.54%) ▼|IBM233.66+1.52 (+0.65%) ▲|INTC93.76+3.91 (+4.35%) ▲|INTU319.82-5.33 (-1.64%) ▼|ISRG430.82+4.12 (+0.96%) ▲|JNJ254.13-1.44 (-0.56%) ▼|JPM338.06-1.66 (-0.49%) ▼|KO93.79-0.11 (-0.12%) ▼|LIN502.01+3.58 (+0.72%) ▲|LLY1,258.36+1.33 (+0.11%) ▲|LMT545.83-6.26 (-1.13%) ▼|LOW195.77-1.61 (-0.82%) ▼|LRCX275.08+11.14 (+4.22%) ▲|MA615.91-1.51 (-0.24%) ▼|MCD241.32-1.66 (-0.68%) ▼|MDLZ63.88-0.03 (-0.05%) ▼|MDT94.07-0.68 (-0.72%) ▼|META694.58-14.75 (-2.08%) ▼|MMM162.89-1.86 (-1.13%) ▼|MO74.42-0.69 (-0.92%) ▼|MRK146.87+0.92 (+0.63%) ▲|MS180.72+0.15 (+0.08%) ▲|MSFT533.03+3.98 (+0.75%) ▲|MU908.23+29.39 (+3.34%) ▲|NEE78.59-1.21 (-1.52%) ▼|NFLX69.30-1.24 (-1.75%) ▼|NKE36.83-0.31 (-0.82%) ▼|NOW143.33+1.36 (+0.96%) ▲|NVDA215.88+1.75 (+0.82%) ▲|ORCL129.36+1.13 (+0.88%) ▲|PEP132.26+0.77 (+0.59%) ▲|PFE29.61+0.03 (+0.08%) ▲|PG158.10-1.25 (-0.78%) ▼|PLTR191.30+5.27 (+2.83%) ▲|PM202.50-2.70 (-1.32%) ▼|QCOM175.67+3.56 (+2.07%) ▲|RTX191.84-2.08 (-1.07%) ▼|SBUX97.14-0.38 (-0.39%) ▼|SCHW90.36-1.60 (-1.74%) ▼|SO89.93-1.25 (-1.37%) ▼|SPG204.06-1.38 (-0.67%) ▼|T23.27-0.18 (-0.75%) ▼|TMO688.56-1.44 (-0.21%) ▼|TMUS157.97-1.13 (-0.71%) ▼|TSLA361.84+7.12 (+2.01%) ▲|TXN276.46-0.03 (-0.01%) ▼|UBER70.27-0.09 (-0.12%) ▼|UNH404.58+3.15 (+0.78%) ▲|UNP287.20-1.84 (-0.64%) ▼|UPS97.27-0.21 (-0.22%) ▼|USB58.37-0.37 (-0.62%) ▼|V402.56-0.05 (-0.01%) ▼|VZ44.39-0.40 (-0.89%) ▼|WFC83.12-0.75 (-0.89%) ▼|WMT118.71-0.10 (-0.08%) ▼|XOM178.01-0.98 (-0.54%) ▼|

10.9 C

New York

Monday, October 19, 2026

Steven D. Linkous Marks 20 Years as President and CEO of Harford Mutual Insurance Group

NxtGen reaffirms its sovereign-cloud commitment and rejects misleading allegations

In HelloNation, Moving Expert Neil Turner Discusses When to Use Professional Packers During a Move

Tag: T cells

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

BRIDGEWATER, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced first clinical proof-of-concept data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The results are being presented today in a late-breaking session at the European Hematology Association (EHA) 2026 Congress (Abstract #LB5006).

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Media Release

COPENHAGEN, Denmark; June 13, 2026

SL BIO Ltd. and Horizon Space Acquisition II Announce Closing of Business Combination and Listing on the Nasdaq Global Market

TAIPEI, Taiwan, June 12, 2026 (GLOBE NEWSWIRE) -- SL BIO Ltd. (“SL Bio” or the “Company”), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, today announced the closing of its previously announced business combination with Horizon Space Acquisition II Corp. (Nasdaq: HSPT) (“Horizon Space”), a publicly traded special purpose acquisition company.

Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China

SHANGHAI and HONG KONG, June 10, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to...

Tevogen Announces Formation of a Healthcare Services Initiative

Tevogen launches Healthcare Services initiative to evaluate MSO and CRO acquisitions with potential to support approximately $100M in annual revenue.

Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma

- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham

- Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in patients with relapsed and refractory neuroblastoma

- Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers

Kali Therapeutics Announces Poster Presentation of KT209, a Novel CD19 x CD20 x CD3 Trispecific Antibody, at the EHA 2026 Annual Congress

SAN MATEO, Calif., June 8, 2026 /PRNewswire/ -- Kali Therapeutics, a clinical-stage biotechnology company pioneering next-generation immune-resetting and multi-specific therapies, today announced that preclinical...

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978

Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026

SHANGHAI and HONG KONG, June 3, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated...

Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

PAPZIMEOS approval marks a historic milestone for the RRP patient community as the first and only FDA-approved therapy for the treatment of adults with...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTagsT cells

Steven D. Linkous Marks 20 Years as President and CEO of Harford Mutual Insurance Group

NxtGen reaffirms its sovereign-cloud commitment and rejects misleading allegations

In HelloNation, Moving Expert Neil Turner Discusses When to Use Professional Packers During a Move

Tag: T cells

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

SL BIO Ltd. and Horizon Space Acquisition II Announce Closing of Business Combination and Listing on the Nasdaq Global Market

Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China

Tevogen Announces Formation of a Healthcare Services Initiative

Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma

Kali Therapeutics Announces Poster Presentation of KT209, a Novel CD19 x CD20 x CD3 Trispecific Antibody, at the EHA 2026 Annual Congress

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026

Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Biotech Stocks Rally as Oncology Market Targets $866B by 2034

Greywolf Therapeutics begins dosing of the first treatment to target the antigenic source of autoimmunity

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us